Latest news with #Q2results
Yahoo
19 minutes ago
- Automotive
- Yahoo
Tesla Faces Cash Crunch Without Tax Credits
Tesla (NASDAQ:TSLA) is taking another hit after those Q2 results landed with a thud. It reported net income falling 16% year-over-year, landing at $1.17 billion, down from $1.39 billion last quarter. Tesla's Q2 2025 revenue declined approximately 14.81% year-over-year, falling from $18.53 billion to $15.79 billion. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Elon Musk even warned we might face a few rough quarters before we hit truly compelling economics by late next here's the kicker: without the $2.8 B in EV tax credits that kept cash flow afloat in 2024, Tesla would actually be bleeding cash. Those credits start disappearing under the Big Beautiful Bill, so margins could get tougher. On the call Musk promised autonomous ride?hailing covering half the US by year?end and pegs Optimus 3 at 100 K robots per month in five years. He also teased a cheaper Model Y in Q4, showed off record Powerwall installs and noted Model Y topped charts in Turkey, the Netherlands, Switzerland and Austria. Why it matters: Slowing sales and political noise are testing Tesla's mojo just as it pins its hopes on robotaxis and will be glued to TSLA's Q3 numbers in October and the rollout of those next?gen products. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
AMETEK's Q2 2025 Earnings: What to Expect
Berwyn, Pennsylvania-based AMETEK, Inc. (AME) manufactures and sells electronic instruments and electromechanical devices. It operates through the Electronic Instruments Group (EIG) and the Electromechanical Group (EMG) segments. With a market cap of $41.1 billion, AMETEK operations span the Americas, Asia, Europe, and internationally. The industrial giant is expected to announce its Q2 results before the markets open on Thursday, Jul. 31. Ahead of the event, analysts expect AME to report a profit of $1.68 per share, up 1.2% from $1.66 per share reported in the year-ago quarter. On a positive note, the company has consistently surpassed Street's EPS projections in each of the past four quarters. More News from Barchart Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? Nvidia Stock Warning: This NVDA Challenger Just Scored a Major Customer Analysts Are Cutting Their Price Targets for UnitedHealth Stock Before Q2 Earnings. Is It Time to Ditch Shares? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full fiscal 2025, AME is expected to deliver an adjusted EPS of $7.10, up nearly 4% from $6.83 in fiscal 2024. Meanwhile, in fiscal 2026, its earnings are expected to grow 6.9% year-over-year to $7.59 per share. AME has gained 3.6% over the past 52 weeks, substantially underperforming the S&P 500 Index's ($SPX) 13.4% returns and the Industrial Select Sector SPDR Fund's (XLI) 19.7% surge during the same time frame. AMETEK's stock prices dipped 1.4% after the release of its mixed Q1 results on May 1. The company's net sales for the quarter dropped by a marginal 24 bps compared to the year-ago quarter to $1.7 billion, missing the Street's expectations by a small margin and unsettling investor confidence. However, the company delivered high single-digit growth in orders, notable margin expansion, and improvement in cash flows. AMETEK's free cash flow for the quarter increased 3.1% year-over-year to $394.5 million. Meanwhile, its adjusted operating margin expanded 60 bps compared to the year-ago quarter to 26.3%, leading to a modest 1.9% year-over-year increase in adjusted operating income to $454.8 million. Moreover, its adjusted EPS grew 6.7% year-over-year to $1.75, exceeding analysts' projections by 3.6%. Following the initial dip, AME stock rebounded 1.7% in the next trading session. The stock holds a consensus 'Moderate Buy' rating overall. Of the 16 analysts covering the AME stock, opinions include 10 'Strong Buys,' one 'Moderate Buy,' four 'Holds,' and one 'Strong Sell.' Its mean price target of $198.07 suggests an 11.2% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Free Malaysia Today
2 days ago
- Business
- Free Malaysia Today
Corporate Malaysia's Q2 earnings likely to be damp squib
Maybank Investment Bank forecasts a modest 2.5% earnings growth for the FBM KLCI in 2025. (Bernama pic) PETALING JAYA : Investors hoping for better second-quarter (Q2) earnings from listed companies will likely be left high and dry as Corporate Malaysia is expected to continue the underperformance of Q1 2025. Maybank Investment Bank (Maybank IB) said the upcoming Q2 results season may be muted, reflecting challenges from external uncertainties, particularly the ongoing US-Malaysia tariff negotiations. 'The Q2 results season may yet be another unexciting one but at least one with fewer earnings downgrades,' it said in a strategy note. The research house forecasts a modest 2.5% earnings growth for the FBM KLCI this year, primarily weighed down by the banking sector. However, it anticipates a stronger rebound in 2026 with a projected growth of 7.7%. It has a base case target of 1,660 points for the FBM KLCI, pegged to 14.4 times 2026 estimated price-to-earnings ratio (PER). 'Our base case assumes further de-escalation in trade tensions and favourable outcome from tariff negotiations,' it added. Some bright spots Despite the softer external environment, Maybank IB said there are 'bright spots' to be found. It noted Malaysia's domestic economic fundamentals appear encouraging, pointing to robust consumer activity, a sustained investment cycle, and signs of resilient private demand as cushioning the impact of weaker exports. The economy grew at 4.5% in Q2, slightly faster than the 4.4% year-on-year growth in Q1 as resilient consumer demand offset weaker exports. This suggests a steady growth momentum and indicates external headwinds due to US tariffs are being mitigated by domestic tailwinds, it noted. Maybank IB said investors should watch out for weakness in the technology sector. Banks are 'unlikely to yield much surprise' even as it watches for lower loan growth. However, it expects some positive momentum for construction, healthcare, property, and more selectively, the oil and gas, and utilities sectors. It said most plantation companies would be weaker quarter-on-quarter due to lower crude palm oil prices, though some could book gains from disposal and forex exchange movements. Consumer and real estate investment trusts are expected to be softer, after a seasonally strong first quarter.
Yahoo
3 days ago
- Business
- Yahoo
ASM reports second quarter 2025 results
Almere, The Netherlands July 22, 2025, 6 p.m. CET Solid Q2 results against a backdrop of continued mixed market conditions ASM International N.V. (Euronext Amsterdam: ASM) today reports its Q2 2025 results (unaudited). Financial highlights € million Q2 2024 Q1 2025 Q2 2025 New orders 755.4 834.2 702.5 yoy change % at constant currencies 56% 14% (4%) Revenue 706.1 839.2 835.6 yoy change % as reported 6% 31% 18% yoy change % at constant currencies 6% 26% 23% Gross profit 352.0 447.8 433.2 Gross profit margin % 49.8 % 53.4 % 51.8 % Operating result 177.6 266.2 258.5 Operating result margin % 25.1 % 31.7 % 30.9 % Adjusted operating result 1 182.3 271.0 263.2 Adjusted operating result margin %1 25.8 % 32.3 % 31.5 % Net earnings (losses) 159.0 (28.9) 202.4 Adjusted net earnings 1 164.7 191.9 173.0 1 Adjusted figures are non-IFRS performance measures. Refer to Annex 3 for a reconciliation of non-IFRS performance measures. New orders of €702 million in Q2 2025 decreased by 4% over the same period last year at constant currency (decreased by 7% as reported). Compared to Q1 2025, orders decreased by 10% at constant currency. This sequential decrease is explained by lower advanced logic/foundry orders due to timing of orders. The y-o-y decrease was mainly due to the lumpy nature of quarterly order intake and compared to a relatively high memory contribution in Q2 2024. Revenue of €836 million increased by 23% at constant currencies (increased by 18% as reported) from Q2 last year. At constant currencies, revenue increased by 7% compared to Q1 2025, which was above our guidance range of +1% to +6% at constant currencies. Revenue in Q2 2025 was driven by foundry, followed by memory, and logic. Gross profit margin of 51.8% in Q2 2025 improved compared to 49.8% in Q2 last year, while it decreased, as expected, compared to 53.4% in Q1 2025. Q2 2025 margin remained healthy thanks to mix, including continued strong sales to China. Adjusted operating result margin of 31.5% increased by 5.7% points compared to the same period last year and slightly decreased by 0.8% points compared to previous quarter. The y-o-y improvement is mainly due to higher gross profit margin this quarter, and a one-off tax charge which resulted in a higher SG&A cost last year. Reported net earnings included a reversal of impairment of €34 million from our stake in ASMPT (Q1 included a €215 million impairment), triggered by the increase in market valuation in the recent period. There is no cash impact. Following the impairment, and in line with our accounting policy, the changes in the market value of ASMPT will be included in our quarterly net results in case of further decline or until the impairment charge has been reversed. Comment 'ASM continued to deliver solid quarterly results against a backdrop of mixed market conditions. Sales increased by 23% year-on-year at constant currencies to €836 million,' said Hichem M'Saad, CEO of ASM. 'Compared to the first quarter of 2025 revenue increased by +7%, which was above the top end of our guidance. The y-o-y increase was led by the logic/foundry segment as well as continued momentum in our spares & services business. The market environment continued to show a mixed picture in the second quarter. Growth in AI is fueling ongoing capacity expansions in the leading-edge logic/foundry and HBM-related DRAM segments, while conditions in most of the other market segments are still slow. Bookings amounted to €702 million in Q2 2025, down 10% compared to Q1 at constant currencies, mainly due to lower advanced logic/foundry bookings. However, the underlying trend in this segment, particularly in gate-all-around (GAA), remains healthy and we expect related leading-edge logic/foundry bookings to pick up again in Q3. The gross margin, while down from a high level of 53.4%, remained strong at 51.8%, again driven by product and customer mix, improved operational efficiency and a better-than-expected contribution from China sales. For the full year 2025, we still expect the gross margin to be in the upper half of the target range of 46%-50%. This excludes any potential direct impact from tariffs, which at this point remains difficult to predict. We have various scenarios in place to mitigate potential financial impacts. Operating profit increased strongly in Q2, by approximately 40% adjusted for a one-off expense last year, on the back of increased sales, gross margin improvement and continued cost control, whilst continuing to invest in R&D. We are well positioned to at least maintain our ALD and epi market share from the first to the second GAA logic/foundry nodes and remain focused on further share gains in memory, as ALD and epi intensity grows in upcoming DRAM nodes.' Outlook We expect revenue in the second half of 2025 to be approximately similar to the level in the first half, at constant currencies. For Q3 2025, we expect total ASM revenue to be flat to slightly lower, in a range of 0% to -5% at constant currencies compared to Q2 2025. As a reminder, with the Q1 2025 results we changed our quarterly revenue guidance from absolute Euro amounts to growth rates at constant currencies, given the increased exchange rate volatility in the recent periods and ASM's significant USD revenue exposure (>80% of sales).For Q3 2025, we expect advanced logic/foundry bookings to be higher than in Q2 2025 and China bookings to be lower, with the overall book-to-bill in Q3 projected to be below 1. Based on comparable sales in the second half versus the first half, we expect revenue growth at constant currencies in 2025 to be around the midpoint of the guidance range of +10% to +20%. We continue to expect to outperform the WFE market, which is forecasted to grow slightly this year. Uncertainties related to tariffs, geopolitical tensions and the overall economic outlook continue to be relatively key growth driver for ASM this year is the high-volume manufacturing ramp of the 2nm GAA node. Despite some further shifts in capex forecasts among customers in this segment, our view for a strong increase in advanced logic/foundry sales in 2025 has not changed. Demand in advanced HBM-related DRAM applications remains solid, but conditions in the other parts of the memory market are sluggish. Against a very strong level last year, we still expect the memory contribution to drop this year (to less than 20% of equipment sales in 2025 versus 25% in 2024). In the power/analog/wafer segment equipment demand remains depressed with no meaningful sales recovery in the remainder of the year, despite some early signs of improvement in the related end markets. Demand in the Chinese market held up better than initially expected in the first half. We now expect China equipment sales in 2025 to be around the top end of the previously guided range of low to high 20s percentage of total ASM revenue. China sales and bookings in the second half are projected to be lower than in the first half. Share buyback program The €150 million share buyback program, announced in February 2025, started on April 30, 2025. On June 30, 2025, 40% of the program was completed at an average share price of €486.48 under ASM's share buyback program (of which 28.6% has been delivered and settled in cash within the reporting period, and the remainder on July 1, 2025). Investor Day We will host our 2025 Investor Day on September 23. Speakers will include our CEO, CFO and other members of ASM's senior management team. Further details will be announced later. Interim financial report ASM International N.V. (Euronext Amsterdam: ASM) today also publishes its Interim Financial Report for the six-month period ended June 30, 2025. This report includes an Interim Management Board Report, including ESG update, and condensed consolidated interim financial statements prepared in accordance with IAS 34 (Interim Financial Reporting). The Interim Financial Report comprises regulated information within the meaning of the Dutch Financial Markets Supervision Act ('Wet op het Financieel Toezicht') and is available in full on our website About ASM ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM's website at Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, pandemics, epidemics and other risks indicated in the company's reports and financial statements. The company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Quarterly earnings conference call details ASM will host the quarterly earnings conference call and webcast on Wednesday, July 23, 2025, at 3:00 p.m. CET. Conference-call participants should pre-register using this link to receive the dial-in numbers, passcode and a personal PIN, which are required to access the conference call. A simultaneous audio webcast and replay will be accessible at this link. Contacts Investor and media relations Investor relations Victor Bareño Valentina Fantigrossi T: +31 88 100 8500 T: +31 88 100 8502 E: E: in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
West Pharmaceutical Services WST is scheduled to release second-quarter 2025 results on July 24, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 18.85%. WST's earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 7.81%. Q2 Estimates Per management, the company expects second-quarter revenues to be in the range of $720 million to $730 million, implying a 3% to 4% organic sales growth. Also, second-quarter adjusted diluted earnings per share (EPS) are expected to be in the range of $1.50 to $1.55. Currently, the Zacks Consensus Estimate for revenues is pegged at $726 million, indicating growth of 3.4% from the year-ago period's level. The consensus mark for earnings is pinned at $1.51 per share, indicating a decline of 0.7% year over year. Our model estimates total revenues to be $722.2 million, implying a 3.2% organic improvement year over year. The adjusted EPS is estimated to be $1.50. While the Proprietary Products segment sales are anticipated to be $583.5 million (organic growth of 4.6%), Contract-Manufactured Products segmental sales are likely to be $138.7 million. Operating profit for the Proprietary Products segment is likely to improve 6.8% whereas for the Contract-Manufactured Products segment, operating profit is likely to decline 14.2%. Factors to Note West Pharmaceutical delivered a solid first-quarter performance in 2025, beating both revenue and earnings expectations. With reported revenues of $698 million and earnings per share (EPS) of $1.45, the company demonstrated resilience despite industry-wide destocking challenges. As the company is poised to post second-quarter results, a segmental analysis suggests a mix of continued growth and stabilization, supported by strategic investments in high-value products (HVPs), contract manufacturing and biologics. In the Proprietary Products segment, West is heading into the second quarter with solid demand trends, particularly for high-value offerings like GLP-1-related components and self-injection platforms. HVPs made up more than 73% of segment revenues in the first quarter, driven by continued strength in GLP-1s. The company is working through a short-term capacity constraint at one facility due to a shift in customer sourcing, which may affect near-term volumes. Pricing came in slightly softer than expected, but not materially so. While some early-quarter challenges could influence growth pacing, management remains confident in a steady pickup in volumes as the year unfolds. Biologics, a key sub-segment within Proprietary Products, is likely to show a mixed but stable performance in the second quarter. The SmartDose platform continued to gain traction in the first quarter, and that momentum is expected to carry into the second quarter as well. However, investors should be mindful that incentive-related comparisons from the back half of 2024 could temper growth in the coming quarters. High-value component volumes in Biologics remained soft due to ongoing destocking trends, and while a more meaningful recovery is anticipated later this year, the second quarter may still reflect some of that gradual normalization. On a positive note, Annex 1 contributed more than expected in the first quarter, benefiting from favorable timing, and while that early lift may normalize in coming periods, the growing project pipeline signals a steady tailwind through the rest of the year. In Contract Manufacturing, WST is navigating a deliberate shift in portfolio dynamics, as growth in GLP-1 auto-injectors helps offset volume declines tied to the wind-down of continuous glucose monitoring (CGM) contracts. This balancing act is expected to remain a theme through the second quarter, with revenue likely to trend stable while the mix continues to evolve. A key part of this transformation is the Dublin facility, which began early-stage commercial production earlier this year and is expected to expand its role over time. The site is being positioned not only for device manufacturing but also as a launchpad for drug-handling capabilities, which WST sees as a natural extension of its expertise. While utilization is still in its early stages, the company indicated that onboarding new drug-handling projects, which come with more attractive margin profiles and lower capital intensity, is progressing as planned. As these programs ramp, they should help smooth out transitional pressures and support a more profitable growth trajectory for the segment in the periods ahead. However, West Pharmaceutical's second-quarter performance is likely to reflect continued macro pressures and inventory-related dynamics, particularly in Biologics. A softer mix of lower-margin delivery devices and reduced volumes in high-margin HVP components may have weighed slightly on gross margins, though operational efficiencies and disciplined cost management likely provided some offset. The company remains focused on long-term margin improvement through automation, including progress toward its new SmartDose production line. West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote What the Zacks Model Unveils Our proven model predicts an earnings beat for WST this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is exactly the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +0.57%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #2 at present. Other Stocks Worth a Look Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time: GeneDx Holdings WGS has an Earnings ESP of +5.26% and a Zacks Rank #2. The company is slated to release second-quarter 2025 results on July 29. WGS' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 145.82%. The Zacks Consensus Estimate for the company's second-quarter EPS is expected to increase 190.9% from the year-ago quarter figure. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is set to release third-quarter fiscal 2025 results on Aug. 6. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. The Zacks Consensus Estimate for COR's fiscal third-quarter EPS is expected to surge 13.2% from the year-ago reported figure. Cardinal Health CAH has an Earnings ESP of +0.81% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2025 results on Aug. 12. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%. The Zacks Consensus Estimate for the company's fiscal fourth-quarter EPS is expected to increase 10.3% from the year-ago quarter figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
